Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/19/2003US20030114444 Analgesics
06/19/2003US20030114443 Viricides, Aids therapy
06/19/2003US20030114442 Reducing concentration of blood lipoproteins
06/19/2003US20030114441 Heterocyclic anti-epileptogenic agents and methods of use thereof
06/19/2003US20030114440 Compositions and methods of treatment for conditions responsive to testosterone elevation
06/19/2003US20030114439 Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
06/19/2003US20030114438 Lactam derivatives as antiarrhythmic agents
06/19/2003US20030114437 Protease inhibitors
06/19/2003US20030114434 Extended duration light activated cancer therapy
06/19/2003US20030114433 Anticancer agents
06/19/2003US20030114432 Antiinflammatory agents; rheumatic diseases; anticancer agents
06/19/2003US20030114431 Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
06/19/2003US20030114430 Aqueous solution; controlling flocculation; oxidation resistance
06/19/2003US20030114429 Pharmaceutical composition for use as a contraceptive
06/19/2003US20030114428 Pharmaceutical compositions for the treatment of asthma
06/19/2003US20030114427 Remedies and/or preventives for nervous system disorders
06/19/2003US20030114426 Method for treating meibomian gland disease
06/19/2003US20030114425 Tiamenidine
06/19/2003US20030114424 Treatment of cerebrovascular disease
06/19/2003US20030114423 Arylamines as inhibitors of chemokine binding to US28
06/19/2003US20030114422 Thrombosis, brain disorders, cardiovascular disorders, Alzheimer's disease, Huntington diseases
06/19/2003US20030114421 Alpha-substituted beta-aminoethyl phosphonate derivatives
06/19/2003US20030114420 Anticancer agents, autoimmunine diseases, congestive heart failure, skin disorders, antiinflammatory agents
06/19/2003US20030114418 Analgesics; antiinflammatory and arthritic agents; osteoarthritis; rheumatic diseases; gastrointestinal, nervous system, respiratory disorders; wound healing agents; vision defects; kits
06/19/2003US20030114416 Analgesics; antiinflammatory, -arthritic agents; vision defects; gastrointestinal and uorgenital disorders; wound healing agents; kits
06/19/2003US20030114415 Compositions and methods for treating and preventing memory impairment using citicoline
06/19/2003US20030114404 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
06/19/2003US20030114403 Administering a triarylmethane dye, e.g. malachite green, or isometamidium chloride that produces an irreversible blockage of the growth of malignant cells without killing them; anticarcinogenic and antitumor agents; leukemia; nontoxic
06/19/2003US20030114400 Oligonucleotide hybridizes with nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha to inhibits gene expression; antiproliferative, -carcinogenic and -inflammatory agents
06/19/2003US20030114398 Monoclonal antiidiotype antibody 1A7 eliciting an anti-ganglioside GD2 response and overcomes immune tolerance; detecting an anti-GD2 antibody bound to a tumor cell; kits; melanoma, neuroblastoma, glioma, soft tissue sarcoma
06/19/2003US20030114397 Water soluble paclitaxel derivatives
06/19/2003US20030114394 Vaginally administered anti-dysrhythmic agents for treating pelvic pain
06/19/2003US20030114393 Use of steroidal alkaloids to reverse multidrug resistance
06/19/2003US20030114392 Process for preparing pseudoephedrine tannate
06/19/2003US20030114391 A therapeutic antihistamine, sustained release, a salt formation of carbinoxamine with tannins
06/19/2003US20030114390 Treating diabetic with a sodium dependent glucose transporters (SGLT2) inhibitors, especially type II diabetes
06/19/2003US20030114389 Combination of organic compounds
06/19/2003US20030114388 Auxiliary agents for ophthalmic operation
06/19/2003US20030114387 Gamma secretase inhibitors
06/19/2003US20030114384 Methods and compositions for treating lesions of the respiratory epithelium
06/19/2003US20030114375 Method for treating cystic fibrosis
06/19/2003US20030114367 Composition for the prevention and/or treatment of artherosclerosis
06/19/2003US20030114365 Neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins; treating neurodegenrative disorders
06/19/2003US20030114364 Administering lactoferrin and glycomacropeptide; microbiocides
06/19/2003US20030114363 Water soluble paclitaxel derivatives
06/19/2003US20030114361 Antithrombotic compound
06/19/2003US20030114360 Peptide of lysine and tyrosine; viricides; treating neurodegenerative disorders
06/19/2003US20030114358 Proteases, lipases and phosphorylases inhibitors
06/19/2003US20030114357 Antidiabetic agents
06/19/2003US20030114356 Method of treating irritable bowel syndrome
06/19/2003US20030114355 Arthroscopic irrigation solution and method for inhibition of pain and inflammation
06/19/2003US20030114354 Computer for producing a three-dimensional representation of a molecule or molecular complex
06/19/2003US20030114353 Calcium channel blockers as antiinflammatory agents
06/19/2003US20030113891 Method and reagent for the inhibition of NOGO and NOGO receptor genes
06/19/2003US20030113869 Human FGF gene and gene expression products
06/19/2003US20030113840 25 human secreted proteins
06/19/2003US20030113822 Identification of anti-protozoal agents
06/19/2003US20030113820 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy
06/19/2003US20030113818 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy
06/19/2003US20030113815 Canine peroxisome proliferator activated receptor gamma
06/19/2003US20030113769 Aminooxy functionalized oligomers, oligomer arrays and methods of using them
06/19/2003US20030113764 Compositions and methods for the treatment of tumors
06/19/2003US20030113763 Oligonucleotide compositions and their use to induce apoptosis
06/19/2003US20030113750 Diagnosing cancer of urogenital systems using oligonucleotides/peptide nucleic acids or cytosine methylation; matrix assisted laser desorption ionization/electron spray mass spectrometry
06/19/2003US20030113393 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/19/2003US20030113392 Proteoglycan compositions for treating arthritic inflammatory conduitions
06/19/2003US20030113389 Wherein dose of jojoba product provides simmondsin component in an amount greater than 0.05 gram/day
06/19/2003US20030113386 For countering or slowing down appearance of signs of ageing of skin
06/19/2003US20030113385 Use of combinations of active agents consisting of antimicrobially active substances and plant extracts containing terpene in veterinary medicine
06/19/2003US20030113382 Causing cyclic GMP to increase in the neoplastic cells and exposing neoplastic cells to cisplatin derivative
06/19/2003US20030113381 Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions
06/19/2003US20030113380 Microparticles comprising polymeric binder and injection vehicle, wherein microparticles are suspended in vehicle at concentration of greater than 30 mg/ml to form suspension having viscosity of 600 cp at 20 degrees C
06/19/2003US20030113379 Biodegradable composite matrix for enhancing angiogenesis and method for producing the same
06/19/2003US20030113377 Orally administered liquid compositions
06/19/2003US20030113376 Omeprazole formulation
06/19/2003US20030113375 Pharmaceutical formulation and process
06/19/2003US20030113373 Delivery of multiple doses of medications
06/19/2003US20030113372 Analgesic in admixture with injectable oil; nalbuphine free base or a pharmaceutically acceptable salt
06/19/2003US20030113371 Composition and method for maintaining blood glucose level by employing the hydrophilic matrix based oral controlled release antidiabetic composition
06/19/2003US20030113370 Method for enabling delivery of an active agent
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003US20030113362 Ascorbate molecules are covalently bound to amino acids
06/19/2003US20030113361 Palatable arginine compounds and uses thereof for cardiovascular health
06/19/2003US20030113359 Prosthetic device placed on the outside surface of the vessel or graft which then elutes antiproliferatives from a matrix
06/19/2003US20030113352 Neutralization of stratum corneum to treat hyperkeratotic skin lesions
06/19/2003US20030113348 Non-laboratory strain used in the manufacture of a medicament for the oncolytic treatment of cancer; anticancer agents
06/19/2003US20030113340 Methods of promoting tolerogenic immune responses and compositions therefor
06/19/2003US20030113335 A conjugate molecule comprising an antitumor drug, a polyglutamate polymer and a targeting molecule; antitumor agents, treating autoimmune disorders such as rheumatoid arthritis, restenosis prevention
06/19/2003US20030113331 An antagonist specifically binds to a denatured collagens; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists
06/19/2003US20030113330 Administering an antagonist of the renin-angiotensin-aldosterone, inhibiting cell apoptosis; treating lung disorders
06/19/2003US20030113323 High mobility group proteins; diagnostic monitoring the severity or potential lethality of sepsis or septic shock, measuring the serum protein concentration of patient, treating weight loss or obesity
06/19/2003US20030113315 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same
06/19/2003US20030113312 Skin barrier function and cohesion through enhanced stratum corneum acidification
06/19/2003US20030113311 Pertussis toxin and analogs exhibit an adenosine-5* diphosphate-ribosyltransferase activity, useful in promoting prophylactic and/or therapeutic responses against another target antigen in a mammal patient
06/19/2003US20030113309 Administering to a patient a compound for increasing neuronal metabolism of histamine to a histamine H2 agonist, to stimulate production of adenosine 3*,5*- cyclic phosphate at a level which maintains myelin against self degeneration
06/19/2003US20030113307 An oil in water emulsion containing an oil phase: a vegetable oil, a coenzyme Q10, an emulsifier, and a water phase containing water; useful therapeutical and nutrient
06/19/2003US20030113292 Interferon-gamma-inducing factor (IGIF/IL-18); promoting differentiation of CD4-lymphocytes
06/19/2003US20030113291 Biocidal polymers based on guanidine salts
06/19/2003US20030113290 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents
06/19/2003US20030113284 Use of DHEA derivatives on keratinous substances
1 ... 5432 5433 5434 5435 5436 5437 5438 5439 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 5451 5452 ... 7860